KRAS G12C in ovarian (mostly low-grade serous) is rare. Tissue- agnostic basket data (Cod...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | G12C |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | sotorasib (off-label tissue-agnostic rationale) |
| Evidence summary | KRAS G12C in ovarian (mostly low-grade serous) is rare. Tissue- agnostic basket data (CodeBreaK 100 multi-tumor cohort) show modest activity. NCCN supports off-label use after standard therapy in G12C+ advanced ovarian. |
Notes
ESCAT IIIA. OncoKB Level 3A. LGSOC may also harbor BRAF V600E (preferred target where co-occurring).
Used By
No reverse references found in the YAML corpus.